Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation. [electronic resource] by
- Ahern, T J
- Morris, G E
- Barone, K M
- Horgan, P G
- Timony, G A
- Angus, L B
- Henson, K S
- Stoudemire, J B
- Langer-Safer, P R
- Larsen, G R
Producer: 19900503
In:
The Journal of biological chemistry vol. 265
Availability: No items available.
|
|
|
5.
|
Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein. [electronic resource] by
- Langer-Safer, P R
- Ahern, T J
- Angus, L B
- Barone, K M
- Brenner, M J
- Horgan, P G
- Morris, G E
- Stoudemire, J B
- Timony, G A
- Larsen, G R
Producer: 19910327
In:
The Journal of biological chemistry vol. 266
Availability: No items available.
|
|
|
6.
|
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity. [electronic resource] by
- Scott, F L
- Clemons, B
- Brooks, J
- Brahmachary, E
- Powell, R
- Dedman, H
- Desale, H G
- Timony, G A
- Martinborough, E
- Rosen, H
- Roberts, E
- Boehm, M F
- Peach, R J
Producer: 20171023
In:
British journal of pharmacology vol. 173
Availability: No items available.
|
|
|
7.
|
Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. [electronic resource] by
- Brinkhous, K M
- Sigman, J L
- Read, M S
- Stewart, P F
- McCarthy, K P
- Timony, G A
- Leppanen, S D
- Rup, B J
- Keith, J C
- Garzone, P D
- Schaub, R G
Producer: 19961107
In:
Blood vol. 88
Availability: No items available.
|